Having trouble accessing articles? Reset your cache.

Zogenix’s Fintepla underwhelms in Phase III for rare epilepsy as data fall short of GW’s Epidiolex

Zogenix lost over $900 million in market cap on Friday after Phase III data for Fintepla to treat Lennox-Gastaut syndrome left investors questioning how well the therapy will compete against GW’s Epidiolex for the rare epilepsy.

While a higher dose of Fintepla fenfluramine oral solution from Zogenix Inc. (NASDAQ:ZGNX) met the primary endpoint of a reduction in the frequency of drop seizures, the placebo-adjusted difference for the dose wasn’t as large as that observed

Read the full 739 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE